{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:50:59Z","timestamp":1794271859003,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01s AI107731"],"award-info":[{"award-number":["R01s AI107731"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI125198"],"award-info":[{"award-number":["AI125198"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004008","name":"National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.celrep.2022.110930","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:59:11Z","timestamp":1654599551000},"page":"110930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity"],"prefix":"10.1016","volume":"39","author":[{"given":"Emily N.","family":"Gallichotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-5778","authenticated-orcid":false,"given":"Sandra","family":"Henein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Nivarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Delacruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Scobey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda M.","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2022.110930_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00440-18","article-title":"Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and -4","volume":"92","author":"Barban","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.110930_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2012.03.007","article-title":"Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D\/dengue viruses","volume":"429","author":"Barban","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.celrep.2022.110930_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.110930_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2022.110930_bib5","doi-asserted-by":"crossref","first-page":"e0234236","DOI":"10.1371\/journal.pone.0234236","article-title":"Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America","volume":"15","author":"Carpp","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2022.110930_bib6","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1016\/j.vaccine.2020.07.056","article-title":"Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.110930_bib7","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2020.03.029","article-title":"Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.110930_bib8","doi-asserted-by":"crossref","first-page":"a029371","DOI":"10.1101\/cshperspect.a029371","article-title":"Which dengue vaccine approach is the most promising, and should we Be concerned about enhanced disease after vaccination? The path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials","volume":"10","author":"de Silva","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.celrep.2022.110930_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2022.110930_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2022.110930_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01559-15","article-title":"Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing","volume":"6","author":"Dowd","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2022.110930_bib12","doi-asserted-by":"crossref","first-page":"e0004398","DOI":"10.1371\/journal.pntd.0004398","article-title":"Incomplete protection against dengue virus type 2 Re-infection in Peru","volume":"10","author":"Forshey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.celrep.2022.110930_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-10-8727-1_5","article-title":"The molecular specificity of the human antibody response to dengue virus infections","volume":"1062","author":"Gallichotte","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.celrep.2022.110930_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.110930_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4269\/ajtmh.18-0534","article-title":"Bridging efficacy of a tetravalent dengue vaccine from children\/adolescents to adults in highly endemic countries based on neutralizing antibody response","volume":"101","author":"Gilbert","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.celrep.2022.110930_bib16","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.110930_bib17","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.110930_bib18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.110930_bib19","doi-asserted-by":"crossref","first-page":"e147066","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2022.110930_bib20","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.110930_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1567-1348(03)00004-2","article-title":"The origin, emergence and evolutionary genetics of dengue virus","volume":"3","author":"Holmes","year":"2003","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.celrep.2022.110930_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/trstmh\/traa154","article-title":"Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children\/adolescents to adults in highly endemic countries","volume":"115","author":"Huang","year":"2020","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.celrep.2022.110930_bib23","doi-asserted-by":"crossref","first-page":"E8378","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A."},{"key":"10.1016\/j.celrep.2022.110930_bib24","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"Dengue viruses cluster antigenically but not as discrete serotypes","volume":"349","author":"Katzelnick","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.celrep.2022.110930_bib25","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1016\/j.vaccine.2017.07.045","article-title":"immune correlates of protection for dengue: state of the art and research agenda","volume":"35","author":"Katzelnick","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.110930_bib26","doi-asserted-by":"crossref","first-page":"20190207","DOI":"10.1098\/rsif.2019.0207","article-title":"Serological inference of past primary and secondary dengue infection: implications for vaccination","volume":"16","author":"Lam","year":"2019","journal-title":"J.\u00a0R. Soc. Interface"},{"key":"10.1016\/j.celrep.2022.110930_bib27","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.110930_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/hv.21224","article-title":"Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore","volume":"8","author":"Leo","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.celrep.2022.110930_bib29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.110930_bib30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.110930_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02041-16","article-title":"Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination","volume":"91","author":"Nivarthi","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.110930_bib32","doi-asserted-by":"crossref","first-page":"e0005554","DOI":"10.1371\/journal.pntd.0005554","article-title":"Dissecting the human serum antibody response to secondary dengue virus infections","volume":"11","author":"Patel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.celrep.2022.110930_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.celrep.2022.110930_bib34","doi-asserted-by":"crossref","first-page":"e24196","DOI":"10.7554\/eLife.24196","article-title":"Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy","volume":"6","author":"Rabaa","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.celrep.2022.110930_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.110930_bib36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.celrep.2022.110930_bib37","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1128\/JVI.00871-13","article-title":"High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.110930_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.110930_bib39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/infdis\/jiw099","article-title":"Homotypic dengue virus reinfections in Nicaraguan children","volume":"214","author":"Waggoner","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.110930_bib40","doi-asserted-by":"crossref","first-page":"e1000821","DOI":"10.1371\/journal.ppat.1000821","article-title":"Natural strain variation and antibody neutralization of dengue serotype 3 viruses","volume":"6","author":"Wahala","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2022.110930_bib41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.meegid.2009.02.003","article-title":"Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease","volume":"9","author":"Weaver","year":"2009","journal-title":"Infect. Genet. Evol."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722007124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722007124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:42:14Z","timestamp":1761910934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124722007124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2211124722007124"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2022.110930","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2022.110930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"110930"}}